WGS vs. PRVA, USPH, PNTG, INNV, TALK, DCGO, SHCR, PIII, EUDA, and ATPC
Should you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Privia Health Group (PRVA), U.S. Physical Therapy (USPH), The Pennant Group (PNTG), InnovAge (INNV), Talkspace (TALK), DocGo (DCGO), Sharecare (SHCR), P3 Health Partners (PIII), EUDA Health (EUDA), and Agape ATP (ATPC). These companies are all part of the "health services" industry.
GeneDx (NASDAQ:WGS) and Privia Health Group (NASDAQ:PRVA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.
GeneDx presently has a consensus price target of $18.00, indicating a potential downside of 12.32%. Privia Health Group has a consensus price target of $25.08, indicating a potential upside of 45.16%. Given Privia Health Group's stronger consensus rating and higher possible upside, analysts clearly believe Privia Health Group is more favorable than GeneDx.
61.7% of GeneDx shares are held by institutional investors. Comparatively, 94.5% of Privia Health Group shares are held by institutional investors. 28.1% of GeneDx shares are held by company insiders. Comparatively, 14.2% of Privia Health Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
GeneDx has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500. Comparatively, Privia Health Group has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
Privia Health Group has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.
Privia Health Group received 52 more outperform votes than GeneDx when rated by MarketBeat users. Likewise, 72.37% of users gave Privia Health Group an outperform vote while only 42.86% of users gave GeneDx an outperform vote.
Privia Health Group has a net margin of 1.11% compared to GeneDx's net margin of -60.86%. Privia Health Group's return on equity of 3.13% beat GeneDx's return on equity.
In the previous week, Privia Health Group had 7 more articles in the media than GeneDx. MarketBeat recorded 13 mentions for Privia Health Group and 6 mentions for GeneDx. Privia Health Group's average media sentiment score of 1.13 beat GeneDx's score of 0.93 indicating that Privia Health Group is being referred to more favorably in the news media.
Summary
Privia Health Group beats GeneDx on 15 of the 18 factors compared between the two stocks.
Get GeneDx News Delivered to You Automatically
Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
